NATCO Pharma announces successful completion of USFDA inspection

NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023

Shilpa Medicare Unit IV, Jadcherla has cleared TGA, Australia GMP inspection

This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years

USFDA inspection at Biocon Biologics' manufacturing facility in Johor, Malaysia

USFDA inspection at Piramal Pharma’s Bethlehem facility

Dishman Carbogen Amcis updates on inspection by EDQM and AIFA

The company's Bavla site was successfully jointly inspected by the EDQM and Italian Medicines Agency (AIFA)

USFDA conducts inspection at InvaGen manufacturing facility in Central Islip, NY, USA

InvaGen has received 5 inspectional observations in Form 483

Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection

The inspection has concluded successfully on 1st September 2023 without any critical/major observation

Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations

The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.

USFDA completes PAD E inspection of Marksans' Goa facility

The inspection was conducted at its Goa, Vema manufacturing facility

USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations